Keith Berelowitz, MSc
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years, having spent the majority of that period working for Richmond Pharmacology. In his role as Director of Operations at Richmond Pharmacology he is focused on the commercial management of the studies we conduct, the efficiency of the company’s functions and oversight of the healthy volunteer and patient recruitment division, integral to the studies conducted by Richmond Pharmacology.

Having played an operational role in over 250 studies, across the commercial, project and recruitment related management of these studies, his specialist area of interest has focused on the assessment and delivery of early and late phase patient trials in a Phase I environment. Keith has worked with a number of sponsors advising them on the viability of conducting such trials within the UK, a number of which have gone on to be conducted successfully with Richmond Pharmacology.

Keith is a member of the National Research Ethics Service Phase 1 Advisory Group (Health Research Authority, UK), Chair of the Fulham Research Ethics Committee and a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and one of the UK representative of the EUCROF Extended Executive Board

Back to experts

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event